Transcode Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Transcode Therapeutics, Inc. (Nasdaq: RNAZ) on October 27, 2025. The report details a material modification to the rights of securityholders regarding the company's Series A and Series B Non-Voting Convertible Preferred Stock. The filing follows a prior transaction on October 8, 2025, involving a Membership Interest Purchase Agreement and Investment Agreement with DEFJ, LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure amendments rather than operational financial performance.
Material Changes Versus Prior Period
On October 27, 2025, the company filed an Amended and Restated Certificate of Designation with the Delaware Secretary of State, modifying the terms established on October 8, 2025. Key changes include:
- Issuance Cap: Clarified that, while the Purchase Agreement is in effect and Preferred Stock remains outstanding, the company cannot issue more than an aggregate of 19.9% of the Common Stock outstanding as of October 8, 2025, prior to stockholder approval of the conversion.
- Delisting Conversion Right Removed: The amendment removed the ability of Preferred Stock holders to convert their shares into Common Stock at their option in the event of a delisting from Nasdaq.
- No New Securities: The filing states that no additional securities were issued or sold as a result of this amendment.
Guidance, Outlook, and Risks
The company expects to file a proxy statement with the SEC to seek stockholder approval for two proposals:
- Conversion Proposal: Approval of the conversion of Preferred Stock into Common Stock in accordance with Nasdaq listing rules.
- Change of Control Proposal: Approval of a "change of control" under Nasdaq Listing Rules 5110 and 5635(b).
Investors are advised that the definitive proxy statement will contain important information regarding the Purchase Agreement, Investment Agreement, and related transactions. The filing identifies the Company, DEFJ, and their respective directors and officers as participants in the solicitation of proxies.
Key Facts for Investor Verification
- Verify the upcoming proxy statement for details on the Conversion and Change of Control proposals.
- Confirm the 19.9% issuance cap on Common Stock relative to the October 8, 2025, outstanding share count.
- Note the removal of the automatic conversion right upon Nasdaq delisting for Preferred Stock holders.
- Review the full text of the Amended and Restated Certificate of Designation (Exhibit 3.1) for complete legal terms.